News Article | November 15, 2016
ReportsnReports.com adds "Bladder Cancer - Pipeline Review, H2 2016" to its store, providing comprehensive information on the therapeutics under development for Bladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy. Complete report on Global Bladder Cancer Market Research with 151 market data tables and 17 figures, spread across 742 pages is available at http://www.reportsnreports.com/reports/747719-bladder-cancer-pipeline-review-h2-2016.html . Company Analysis and Positioning discussed in this research are 4SC AG, Adaptimmune Therapeutics Plc, ADC Therapeutics SA, Agenus Inc, Altor BioScience Corporation, AndroScience Corporation, APIM Therapeutics AS, Arno Therapeutics, Inc., Astellas Pharma Inc., Astex Pharmaceuticals Inc, Aura Biosciences, Inc., AVEO Pharmaceuticals, Inc., Azaya Therapeutics, Inc., Bavarian Nordic A/S, Bayer AG BioCancell Ltd, Biomics Biotechnologies Co., Ltd., Bioncotech Therapeutics SL, Biotest AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Cellceutix Corporation, Celldex Therapeutics, Inc., Celprogen, Inc., Celsion Corporation, Codagenix, Inc., Cold Genesys, Inc., Corvus Pharmaceuticals Inc, CytomX Therapeutics, Inc., DormaTarg, Inc., Eisai Co., Ltd., Eleven Biotherapeutics Inc., Eli Lilly and Company, Elsalys Biotech SAS, enGene, Inc, Esperance Pharmaceuticals, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Gene Signal International SA, Genmab A/S, GlaxoSmithKline Plc, H3 Biomedicine Inc., Hamlet Pharma AB, Heat Biologics, Inc., HEC Pharm Co., Ltd., Hutchison MediPharma Limited, Idera Pharmaceuticals, Inc., ImmuNext, Inc., Immunocore Limited, Immunomedics, Inc., Immupharma Plc, InteRNA Technologies B.V., Johnson & Johnson, LipoMedix Pharmaceutical Inc., MacroGenics, Inc., MaxiVAX SA, Meabco A/S, Medicenna Therapeutics, Inc., MedImmune LLC, Merck & Co., Inc., Merck KGaA, Mirati Therapeutics Inc., Mirna Therapeutics, Inc., Miyarisan Pharmaceutical Company, Ltd, Moleculin Biotech Inc, NanoCarrier Co., Ltd., Nektar Therapeutics, NuCana BioMed Limited, Omeros Corporation, Oncogenex Pharmaceuticals, Inc., Oncolytics Biotech Inc., OncoTherapy Science, Inc., Ono Pharmaceutical Co., Ltd., Optimum Therapeutics, LLC, Pfizer Inc., Pharma Mar, S.A., Philogen S.p.A., Plexxikon Inc., Polaris Pharmaceuticals, Inc., Provectus Biopharmaceuticals, Inc., PsiOxus Therapeutics Limited, Rexahn Pharmaceuticals, Inc., Rodos BioTarget GmbH, Sanofi, Savoy Pharmaceuticals, Inc., Serometrix, LLC, Shionogi & Co., Ltd., Sillajen Biotherapeutics, Sorrento Therapeutics Inc, Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Sun Pharma Advanced Research Co Ltd, Synovo GmbH, Taiwan Liposome Company, Ltd., Tara Immuno-Oncology Therapeutics LLC, Taris Biomedical LLC, Telormedix SA, TesoRx Pharma LLC, Theravectys SA, Theryte Limited, Transgene SA, UroGen Pharmaceuticals, Ltd., Vakzine Projekt Management GmbH, Vault Pharma Inc., Vaxeal Holding SA, Vaxiion Therapeutics, Inc. and Viralytics Ltd. The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 44, 35, 2, 56 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively. Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:
News Article | December 2, 2016
NEW YORK and CARLSBAD, Calif. and SAN FRANCISCO, Dec. 2, 2016 /PRNewswire/ -- San Francisco will be the center of biopharma innovation and investment January 9–11, 2017 at Biotech Showcase™, the leading biotech investor event of the year produced by Demy-Colton and EBD Group. Over 3,000 delegates are expected to attend the event, considered to be a critical strategic gathering for the industry's most innovative biotech companies to connect with global life science decision makers and investors from across the drug development ecosystem. "Biotech Showcase is the place to be in January. You will meet the right people at the right time, and it's a great start to the year to invigorate your business networking. The value that the event provides is the high caliber of the 300+ small/mid-cap public and private presenting companies and the 550+ investors participating," said Sara Jane Demy, Founder and CEO, Demy-Colton. "Now in its ninth year, we expect Biotech Showcase to grow 20% in attendance this year. We have expanded the event to two adjacent locations, with an exciting new format which includes two concurrent events, Medtech Showcase and Digital Medicine Showcase. It really is the event where innovation meets money every January," said Anna Chrisman, Group Managing Director, EBD Group. An estimated USD 40 billion plus in capital will be represented at Biotech Showcase by attending investors, including institutional, private equity, angel and venture investors who actively invest in innovative life sciences and biotech companies. Using a proven format, international biotech companies ranging from public mid- and small-cap to private venture and angel-backed private life science companies, present to investors and strategic partners, conduct one-to-one meetings and participate in informal networking. A robust program complements this activity with panels and workshops focused on the latest industry trends featuring key biotech leaders, investors, pharma executives, and other industry advisors. Headlining the program this year are Jeffrey Brewer, President and CEO, Bigfoot Biomedical; Alan Dunton, Senior VP, Research and Development, Purdue Pharma L.P.; Lee Jones, President and CEO, Rebiotix; Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk; Robert Millman, CEO, Semma Therapeutics; Flemming Ornskov, CEO, Shire; and Henri Termeer, Former CEO of Genzyme and Board Member, Aura Biosciences. For more information or to register for the event, go to BiotechShowcase.com. Demy-Colton produces high level investor and business development conferences and events for the biopharmaceutical and life sciences industry. With a proven track record and deep domain knowledge, it develops programs that add value and regularly exceed the expectations of participants. Dedicated to facilitating the growth of the life sciences industry, Demy-Colton's expanding portfolio of conferences includes: EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. EBD Group's conferences are run with the support of leading corporations and international trade associations and include: EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year. Tune into EBD Group's Insight for timely coverage of news that influences the business strategies of the life science industry. EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world. EBD Group has offices in the USA and Europe. For more information please visit www.ebdgroup.com.
Aura Biosciences | Date: 2012-02-06
The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases.
Aura Biosciences | Date: 2012-01-17
This invention relates to a transdermal delivery system for treating skin related diseases employing protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of non-melanoma skin cancer. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.
Aura Biosciences | Date: 2013-02-07
The invention relates to methods for producing papilloma-derived nanosphere particles that contain therapeutic, diagnostic, or other agents. The invention also provides nanosphere particle preparations that are useful for selectively delivering therapeutic, diagnostic, and/or other agents to cancer cells of subjects without eliciting a serotype-specific immunogenic response in the subjects.
Aura Biosciences and The United States Of America | Date: 2014-09-18
The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
Aura Biosciences | Date: 2011-10-13
This invention relates to a transdermal delivery system for treating skin related diseases employing protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of Psoriasis. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.
Aura Biosciences | Date: 2012-01-23
This invention relates to a transdermal delivery system for treating skin related genetic diseases. More specifically, the present invention provides particles and methods for using pseudo-viruses, including those derived from the herpes and papillomaviruses, to deliver drugs to keratinocytes and basal membrane cells for the treatment of skin genetic disorders including Pachyonychia Congenita and Xeroderma Pigmentosum.
Aura Biosciences | Date: 2011-10-03
This invention relates to a transdermal delivery system for treating skin related diseases employing papilloma-derived protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of alopecia. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.
Aura Biosciences | Date: 2012-05-11
The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases. The nanoparticles of the present invention are designed to deliver radioactive isotopes suitable for imaging a tumor and its metastases. Additionally, the nanoparticles may deliver a radioisotope that is suitable for treating a tumor and its metastases by alpha, beta or gamma radiation. Alternatively, the virion derived nanoparticles may deliver a treatment agent for cancer or a combination of a radioisotope and a cancer treatment agent. Additionally the virion derived nanoparticle may include delivery of a drug that enhances the immune systems recognition of the tumor.